Movement Alert｜Elevance Health Rises 3.08% in Regular Trading, Multiple Banks Raise Price Targets Fueling Post-Earnings Recovery

Market Focus07-20

On July 20, Elevance Health rose 3.08% in regular trading, trading near $385.11/share, with turnover of approximately $74.15 million. The stock continued its recovery from the post-Q2 earnings sell-off.

The rebound is being driven by a wave of analyst price target increases following the company's strong Q2 results. Guggenheim raised its target to $455, Truist to $475, and Leerink to $395. Truist lifted its full-year EPS estimate to $27.12 and its fiscal year forward estimate to $29.14, citing Q2 outperformance and improved guidance as a foundation for long-term expectations. The company reported Q2 adjusted EPS of $7.45, beating consensus of $6.21 by nearly 20%, and raised full-year adjusted EPS guidance to at least $27.00.

Despite the beat, the stock had initially fallen approximately 10% on the earnings release date due to concerns over Medicaid utilization pressure and planned market exits over the next 12-18 months. The current move reflects a normalization as the Street digests the magnitude of the earnings surprise against the Medicaid headwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115363093?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115363093","market":"us","top_or_hot":-1,"title":"Movement Alert｜Elevance Health Rises 3.08% in Regular Trading, Multiple Banks Raise Price Targets Fueling Post-Earnings Recovery","media":"Market Focus","content":"<p><p>On July 20, Elevance Health rose 3.08% in regular trading, trading near $385.11/share, with turnover of approximately $74.15 million. The stock continued its recovery from the post-Q2 earnings sell-off.</p><p>The rebound is being driven by a wave of analyst price target increases following the company's strong Q2 results. Guggenheim raised its target to $455, Truist to $475, and Leerink to $395. Truist lifted its full-year EPS estimate to $27.12 and its fiscal year forward estimate to $29.14, citing Q2 outperformance and improved guidance as a foundation for long-term expectations. The company reported Q2 adjusted EPS of $7.45, beating consensus of $6.21 by nearly 20%, and raised full-year adjusted EPS guidance to at least $27.00.</p><p>Despite the beat, the stock had initially fallen approximately 10% on the earnings release date due to concerns over Medicaid utilization pressure and planned market exits over the next 12-18 months. The current move reflects a normalization as the Street digests the magnitude of the earnings surprise against the Medicaid headwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Elevance Health Rises 3.08% in Regular Trading, Multiple Banks Raise Price Targets Fueling Post-Earnings Recovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Elevance Health Rises 3.08% in Regular Trading, Multiple Banks Raise Price Targets Fueling Post-Earnings Recovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-20 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 20, Elevance Health rose 3.08% in regular trading, trading near $385.11/share, with turnover of approximately $74.15 million. The stock continued its recovery from the post-Q2 earnings sell-off.</p><p>The rebound is being driven by a wave of analyst price target increases following the company's strong Q2 results. Guggenheim raised its target to $455, Truist to $475, and Leerink to $395. Truist lifted its full-year EPS estimate to $27.12 and its fiscal year forward estimate to $29.14, citing Q2 outperformance and improved guidance as a foundation for long-term expectations. The company reported Q2 adjusted EPS of $7.45, beating consensus of $6.21 by nearly 20%, and raised full-year adjusted EPS guidance to at least $27.00.</p><p>Despite the beat, the stock had initially fallen approximately 10% on the earnings release date due to concerns over Medicaid utilization pressure and planned market exits over the next 12-18 months. The current move reflects a normalization as the Street digests the magnitude of the earnings surprise against the Medicaid headwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELV","symbol_name":"Elevance Health","start_time":0,"source_url":"","article_id":"1115363093","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115363093","pubTimestamp":1784555740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 20, Elevance Health rose 3.08% in regular trading, trading near $385.11/share, with turnover of approximately $74.15 million. The stock continued its recovery from the post-Q2 earnings...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ELV":"Elevance Health"},"translate_title":"走势警报|Elevance Health 常规交易中上涨 3.08%，多家银行上调价格目标，推动财报后复苏","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELV":1},"content_text":"On July 20, Elevance Health rose 3.08% in regular trading, trading near $385.11/share, with turnover of approximately $74.15 million. The stock continued its recovery from the post-Q2 earnings sell-off.The rebound is being driven by a wave of analyst price target increases following the company's strong Q2 results. Guggenheim raised its target to $455, Truist to $475, and Leerink to $395. Truist lifted its full-year EPS estimate to $27.12 and its fiscal year forward estimate to $29.14, citing Q2 outperformance and improved guidance as a foundation for long-term expectations. The company reported Q2 adjusted EPS of $7.45, beating consensus of $6.21 by nearly 20%, and raised full-year adjusted EPS guidance to at least $27.00.Despite the beat, the stock had initially fallen approximately 10% on the earnings release date due to concerns over Medicaid utilization pressure and planned market exits over the next 12-18 months. The current move reflects a normalization as the Street digests the magnitude of the earnings surprise against the Medicaid headwinds.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115363093","isCrawlerRequest":true}